Is Supernus Pharmaceuticals, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Supernus Pharmaceuticals, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 29, an EV to EBITDA of 9.02, and a Price to Book Value of 1.80. In comparison, PTC Therapeutics, Inc. has a P/E ratio of 5.85 and EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a more favorable P/E of 11.40 and EV to EBITDA of 6.94, highlighting the relative overvaluation of Supernus.
Despite the company's strong recent performance, with a year-to-date return of 38.74% compared to the S&P 500's 13.30%, the elevated valuation ratios suggest that the stock may not be a sustainable investment at its current price level.